GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Question] how do you actually verify SURPASS — 35 comments in the full submission. View in context.
2.9k
c/trialwatch·submitted 1 year ago by u/marit_laurent

[Question] how do you actually verify SURPASS

Readoutbranch of 7 comments

how do you actually verify SURPASS. I would rather ask a basic question now than get this wrong quietly for two months. The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table. Argued for a week about a result and then read the limitations section, which…

Read the full submission and all 35 comments →

This branch

7 comments, started 1 year ago
u/first_hundred261 points·1 year ago

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

replysharereportpermalink
u/formulary_fighterappeals207 points·1 year ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/emil_agyeman74 points·1 year ago

trial populations get support that nobody on this board gets

replysharereportpermalink
[removed]30 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/foam_head_fred22 points·1 year ago

registry entry, protocol, publication — three different documents

replysharereportpermalink
u/zaid_roos38 points·1 year ago

discontinuation rate is a result, not a footnote

replysharereportpermalink
u/week_one_wanda65 points·1 year ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →